Navigation Links
WebMD Launches New Consumer Health Portal in the U.K.
Date:10/21/2009

f Executive, Health & Beauty, Alliance Boots. "A more informed healthcare consumer leads to a more productive physician interaction."

Boots will launch a national marketing and consumer education effort to its large UK customer base to promote the new site, through in-store marketing, in its health and beauty magazines, on its heavily trafficked e-commerce site and to its large base of loyalty program members. In addition, Boots UK has engaged its thousands of pharmacists to create awareness of the site and its offerings during their frequent patient interactions.

About WebMD

WebMD Health Corp. (Nasdaq: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers and health plans through our public and private online portals and health-focused publications. WebMD Health Corp. is a subsidiary of HLTH Corporation (Nasdaq: HLTH). Approximately 60 million unique visitors access the WebMD Health Network each month.

The WebMD Health Network includes WebMD Health, Medscape, MedicineNet, eMedicine, eMedicine Health, RxList and theHeart.org.

About Boots UK

Boots is a member of Alliance Boots, an international pharmacy-led health and beauty group. Alliance Boots is privately-owned and employs over 115,000* people. Its wholesale and distribution network serves over 140,000* pharmacies, doctors, health centres and hospitals from over 370* pharmaceutical wholesale distribution centres in 16* countries. Boots operates more than 3,200* health and beauty retail stores in nine* countries, of which just under 3,000* have a pharmacy.

* Figures stated are as at 31 March 2009, are approximate and include associates and joint ventures.

All statements contained in this press release,
'/>"/>

SOURCE WebMD
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders
2. Starch Medical Launches Novel Plant Sourced Surgical Hemostatic Pad
3. Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
4. Prometheus Launches ProOnc Dx Cancer Diagnostics
5. Frutarom Launches New Global Branding
6. Cantel Medicals Crosstex Subsidiary Launches New Specially Treated Face Mask Effective Against H1N1 Influenza
7. Iowas Largest Health System Launches First-in-the-Nation Statewide Electronic Prescribing
8. Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation
9. MO BIO Laboratories, Inc. Launches LifeGuard(TM) Soil Preservation Solution
10. AMICAS Launches Major New Version of Radiology Information System at RBMA 2009
11. PARI Respiratory Launches PEP S
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... 4 A new, $2.8 million, four-year federal grant ... of Medicine and their collaborators at Wake Forest University ... blood degrades over time and how to address the ... been associated with increased risk for cardiovascular events and ...
(Date:12/4/2009)... Deliveries are Transported ,, PHILADELPHIA, Dec. 4 ... the American Red Cross are hard at work educating ... endure that could potentially put Philadelphia,s blood supply at ... and set up a picket line yesterday when their ...
(Date:12/4/2009)... Imaging, LLC, an independent provider of CT, MRI ... and healthcare providers, is excited to announce it ... Health Care, a nationally-recognized, prestigious gold seal of ... Shared Imaging accreditation is system-wide for its mobile ...
Breaking Medicine Technology:NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 2NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 3Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2The Prem Rawat Foundation Makes Two Grants to Provide Relief in Pakistan 57584 1The Prem Rawat Foundation Makes Two Grants to Provide Relief in Pakistan 57584 2Ohio Healthcare Organization Responds to Healthcare Reform 57581 1Ohio Healthcare Organization Responds to Healthcare Reform 57581 2Ohio Healthcare Organization Responds to Healthcare Reform 57581 3Ohio Healthcare Organization Responds to Healthcare Reform 57581 4Ohio Healthcare Organization Responds to Healthcare Reform 57581 5FDA Warns Consumers Not to Use Stolen Albuterol Sulfate Inhalation Solution and Ipratropium Bromide Inhalation Solution 57579 1FDA Warns Consumers Not to Use Stolen Albuterol Sulfate Inhalation Solution and Ipratropium Bromide Inhalation Solution 57579 2
... TriLipix in Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar ... ... Population, SAN FRANCISCO, June ... dyslipidemia and type 2 diabetes,that were enrolled in a Phase III ...
... Annual Scientific Sessions, SAN FRANCISCO, June 7 ... dose-finding study for its new,injectable diabetes compound AVE0010, ... Association,s (ADA) 68th Annual Scientific Sessions,meeting in San ... was well tolerated and significantly,improved glycemic control versus ...
Other Medicine Technology:Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 2Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 3Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 4New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4
(Date:12/7/2009)... NEW ORLEANS, Dec. 7 Cell Therapeutics, ... that Ruth Pettengell, M.D. of St. George,s Hospital, ... 2009 American Society of Hematology ("ASH") Annual Meeting ... (PIX 301) clinical trial of pixantrone (the "PIX ... non-Hodgkin,s lymphoma ("NHL") patients who have failed ...
(Date:12/6/2009)... ORLEANS and SUNNYVALE, Calif., Dec. 6 ... interim results from a Phase I/II study showing ... / recurrent non-Hodgkin,s Lymphoma (NHL) treated with its ... data were presented today at the 51st ASH ... (Abstract # 2726). ,, PCI-24781 is an ...
(Date:12/6/2009)... signs of feline DNA in virus , , SUNDAY, Dec. 6 ... AIDS might be found in a tiger that lived thousands ... It appears the virus took on a bit of a ... cat remains in the virus to this day. That tiger, ... evolution of the virus that ultimately led to its infection ...
(Date:12/6/2009)... ON. Dec. 6, 2009 A new study provides ... known as venous thromboembolism (VTE). , The condition ... every year, and occurs when an abnormal clot forms ... causing pain and swelling. In some cases, the clot ... through the heart to the lungs, causing a potentially ...
(Date:12/5/2009)... significant scientific advances in the field of blood cancers, ... of how certain diseases progress in order to discover ... care. Research presented today at the 51st Annual Meeting ... therapies for managing multiple myeloma, the importance of advance ...
Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8
... Against Widex and William Demant Companies, SALT LAKE ... ), a leading producer of advanced digital hearing aids,issues ... of press,releases related to a jury award of $31 ... Inc. v. Sonic Innovations,Inc., et al. While this action ...
... The first genome-wide search for genes governing social behavior ... the amoebae Dictyostelium discoideum -- have more than 100 ... study by scientists at Rice University and Baylor College ... the journal Nature. It marks one of the first ...
... Senior Living Inc.,(NYSE: BKD ) announced today that ... 2007 financial results after the market closes on Wednesday,February ... to discuss,the results on February 28, 2008 at 10:00 ... (866) 845-7252 (from within the U.S.) or (706) 634-9069,(from ...
... at The Wistar Institute have collaborated on a major advance ... the deadliest cancers in humans. The culmination of 10 years ... new cancer therapies. , During much of its lifetime, ... in an inactive form, stored inside densely knotted structures in ...
... to close FMLA loopholes, ALEXANDRIA, Va., Feb. ... devoted to human resource management,appeared before a Senate ... the,Family Medical and Leave Act (FMLA) be closed., ... have two primary concerns with the act,s,regulations--the definitions ...
... first quarter operating results further convinces ... a discount, NEW YORK, Feb. 13 Accipiter ... 10% of the outstanding,shares of common stock of VistaCare, ... delivered a letter to VistaCare,s Board of Directors stating,that ...
Other Medicine News:Health News:Sonic Innovations Not Included in Adverse Jury Verdict 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 3Health News:Brookdale Announces Fourth Quarter and Full Year 2007 Release and Earnings Call 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 3Health News:Is a Common Cold a 'Serious Health Condition'? 2Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 2Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 3Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: